Tools
Upgrade to Pro 🌟

Upgrade for Pro stock ideas, Al signals, and more search.

Learn More

SMMT

Summit Therapeutics Inc · NASDAQ

Performance

+15.17%

1W

+13.16%

1M

+127.77%

3M

+303.2%

6M

+720.31%

YTD

+1073.15%

1Y

Profile

Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Technical Analysis of SMMT 2024-11-08

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 70 further supports this positive outlook. However, the Oscillators Score of 50 suggests a neutral stance, indicating potential consolidation or indecision in the market, which could temper the overall ...
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of SMMT

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.